Citizens Reiterates Market Outperform Rating on Madrigal Pharmaceuticals (MDGL) Amid Rezdiffra Momentum
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $485.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
